Deepu Madduri, MD, discusses findings from the CARTITUDE-1 trial, in which the new CAR T-cell therapy candidate led to a 100% response rate and high rates of minimal residual disease negativity in patients with relapsed/refractory multiple myeloma.
Advertisement intended for health care professionals
Deepu Madduri, MD, discusses findings from the CARTITUDE-1 trial, in which the new CAR T-cell therapy candidate led to a 100% response rate and high rates of minimal residual disease negativity in patients with relapsed/refractory multiple myeloma.
Advertisement intended for health care professionals